Arterial Stiffness Clinical Trial
Official title:
Pulse Wave Velocity as a Predictor for Postoperative Cardiovascular Events
Vascular stiffness increases as a person ages, due to the repetitive stress that is put on
the vascular system which causes changes in the elasticity of the vessel walls. The increased
stiffness of the arteries puts added stress on the circulatory system. This rise in stiffness
has been shown to be associated with an increased risk of cardiovascular events, in both
presumably healthy patients, as well as elderly patients The current method for assessing
perioperative cardiac risk is the Goldman's Revised Cardiac Risk Index (RCRI). This method,
however, does not include a direct measurement of arterial stiffness. Applanation tonometry
is a non-invasive technique that has been shown to reliably provide indices of arterial
stiffness While the use of applanation tonometry has been widely studied in general medicine,
it is has not been studied for pre-operative risk assessment in surgical patients.
The purpose of this investigation is to examine whether aortic stiffness is an independent
risk factor for developing cardiovascular related adverse events in patients who are having
major surgery under general anesthesia.
Applanation tonometry will be performed on the right carotid and femoral arteries to assess
carotid-femoral pulse wave velocity, a surrogate for aortic stiffness. (SphygmoCor system,
AtCor Medical, Sydney, Australia). The measurement will be obtained before induction of
general anesthesia in the presurgical area. Patients' medical history, intraoperative
hemodynamics, and any postoperative complications will be recorded to determine significant
correlations and relationships. This information will potentially help identify future
patients that might be at greater risk of developing an adverse cardiovascular event
following their surgical procedure.
Background: In 1894 William Osler, MD, said: "You are as old as your arteries." A number of
recent studies have confirmed this prescient proclamation. Vascular rather than chronological
age is the best predictor of adverse cardiovascular events and mortality from coronary
insufficiency, ischemia, myocardial infarction, heart failure, cerebrovascular insufficiency
or stroke, and renal insufficiency or failure. We believe it is likely this also applies to
perioperative risk of cardiovascular complications from the numerous stress factors
associated with major surgery.
Vascular aging leads to central aortic dilation, arterial wall thickening of the media and
adventitia with sclerotic changes and increased vascular stiffness. These changes lead to
central blood pressure (BP) augmentation, elevated systolic and pulse pressure, along with
lowered diastolic BP. (1) Central more elastic vessels cushion and dampen pressure
oscillations with left ventricular (LV) ejection and transfer this stored energy into
continuing antegrade pulse waves along the arterial tree during diastole. (2) the pulse wave
is also reflected back centrally when it meets higher flow resistance at major artery branch
points and muscular arteries resulting in central aortic combination wave. In a younger
compliant central aorta the reflected waves arrive after aortic valve closure, augmenting
early diastolic perfusion pressure an coronary blood flow. Elderly stiff aorta and major
arteries vessels transfer both antegrade and retrograde pulse waves faster. If heart rate is
slow enough an asystole long enough, this combination wave will arrive at the central aorta
during late systole. This elevates LV workload, resulting in compensatory left ventricular
hypertrophy (LVH). In addition, disappearance of the diastolic combination wave lowers
coronary perfusion pressure, increasing the risk of coronary insufficiency for the
hypertrophied LV wall.
Unfortunately, high blood flow coronary, and renal arteries are not so muscular that they can
reduce the impact of high combination systolic pressure waveforms. This induces chronic
kinetic injury to these high blood flow vessels and organs. Increased pulsatility leads to
arterial remodeling and microcirculation damage in brain and kidney, small lacunare infarcts,
white matter lesions associated with cognitive dysfunction and dementia, while endothelial
dysfunction compromises cerebral blood flow, the blood-brain barrier and renal perfusion.
Again, LVH from elevated combination waveform pressure leads to diastolic dysfunction and
heart failure. Thus, elevated pulse wave velocity (PWV)and central aortic pulse augmentation
indices are independent predictors of CAD, stroke, renal dysfunction, and all-cause
mortality. (1) It is responsible for the rising risk of myocardial insufficiency, ischemia,
LVH, and heart failure, cerebrovascular insufficiency or injury as well as renal injury and
impairment with vascular aging.
The rate of vascular aging is multifactorial, including genetic susceptibilities as well as
acceleration from vascular disease such as hypertension, atherosclerosis and diabetes. Recent
trials have shown ACE inhibitors, angiotensin II blocks (ARBs) and Ca++ channel blockers have
favorable effects on central aortic compliance, reducing LVH and reducing the risk of heart
failure, stroke and renal impairment. In contrast, Beta blockers enhance central aortic BP
augmentation by lengthening LV ejection time. Thus the reflected pulse waves arrive during
late systole, augmenting the combined central aortic wave amplitude and LV workload.
Pulse wave velocity (PWV)has become a very good measure of aortic stiffness. PWV rises from
6m/sec in a young person to 10m/sec in a 65 y/o. It increases 2-fold from 20-80 y/o, due to a
4-fold reduction in aortic distensibility. (3) The CAFE study showed significant reduction in
central artic BP and adverse cardiovascular events as well as renal impairment with Ca++
channel blockers, but not with atenolol plus thiazide Rx. (4) The REASON study showed ARBs
reduced vascular stiffness, wave reflections, central aortic pulse pressure, vascular
resistance, remodeling and thickness of resistance vessels. (5) Method/Design: The study will
be human subject non-randomized observational study. This study will enroll approximately 500
patients. This was determined by a preliminary analysis of 140 patients, of which 19 had
adverse cardiovascular events, within a week after surgery. The results of this preliminary
study found average PWV was significantly higher in patients who developed postoperative
cardiovascular events compared with patients who had uneventful postoperative course.
(p-value 0.024). Therefore it was determined that 500 patients should be sufficient to see a
statistically significant difference if there is one. This study will be conducted at day of
surgery administration area and main operation room at University of Iowa Hospitals and
clinics. Arterial stiffness will be measured at day of surgery administration area prior to
the surgery. Carotid-Femoral Pulse Wave Velocity (Aortic Stiffness).
Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using
the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery
waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the
right common carotid artery and over the right femoral artery. The time (t) between the feet
of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac
cycles. PWV is calculated by the system software from the distance between measurement points
(D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/ s) where D is distance in
meters and t is the time interval in seconds.
After consent, the subject will be taken to a private exam room where a noninvasive study of
PWV and central aortic BP will be performed in supine position using the SphygmoCor sensor
positioned over the carotid and femoral or radial artery pulse waveform, along with 3-lead
EKG for QRS timing of the onset of systole. The SphygmoCor pulse wave sensor will be
calibrated with an upper arm sphygmomanometer cuff BP. The vascular aging measurements will
not be used to guide or alter medical decision making in the study. The study will take
approximately 30 min. They will also not be repeated for this protocol either during or after
surgery.
Pre and intraoperative data collection will include: ASA status, history of peripheral
vascular disease, history of ischemic vascular disease, history of congestive heart failure,
and history of cerebrovascular disease, intraop: all of the routine vital signs, anesthetic
drug details, fluids, blood loss, and urine output data relevant to the surgical procedure.
Any significant clinical AEs such as brady- or tachycardia (HR <50 or >100 for >10 min),
hyper- or hypotension (BP >30% above or > 30% below awake), EKG rhythm or ST segment
abnormality, abnormal BIS (anesthetic depth) or other EEG issue during anesthesia or surgery,
and wake up difficulty will be documented in the clinical anesthesia electronic record. All
other relevant monitoring data such as hypoxemia (pulse oximeter), hypo-or hyperventilation
(capnography or arterial blood gas values) will be recorded in a clinical data file for each
subject.
Postoperative data collection will include vital signs and any clinical cardiac, neurological
or renal adverse events or other complications especially for the first 30 days, and any
later events including all-cause mortality up to one year after surgery. Postoperative
outcome information will be primarily collected via the medical record review. We do not plan
to visit study subjects at bedside while recovering from surgery as inpatients, and will not
schedule additional outpatient research follow up visits. However we also plan to call
enrolled subjects at 1, 6, and 12 months after surgery to ask them whether they have
experienced postoperative complications such as a a stroke, myocardial infarction,
dysrhythmia such as atrial fibrillation, heart failure, respiratory failure, kidney function
problem, renal failure or death.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06133634 -
Fisetin to Improve Vascular Function in Older Adults
|
Phase 1/Phase 2 | |
Completed |
NCT05872139 -
Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging
|
N/A | |
Recruiting |
NCT04558450 -
Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)
|
N/A | |
Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
Not yet recruiting |
NCT05943457 -
Vitamin K2 Supplementation in Adult Episodic Migraine
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Completed |
NCT02226055 -
An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka
|
N/A | |
Completed |
NCT01559896 -
Egg Protein Hydrolysate and Vascular Function
|
N/A | |
Completed |
NCT04049162 -
Blueberry Enhances Activity and Cognition Through Increased Vascular Efficiency
|
N/A | |
Not yet recruiting |
NCT06440369 -
Physical Activity and Cardiovascular Risk
|
N/A | |
Completed |
NCT05537246 -
The Relationship Between Arterial Stiffness and Hemodynamic Responses in Patients With Spinal Anesthesia
|
||
Completed |
NCT06151054 -
Relationship Between Aortic Parietal Inflammation on 18F-FDG PET Scan and Arterial Stiffness as a Function of Age
|
||
Completed |
NCT02218268 -
Arterial Stiffness in Type I Diabetes Mellitus
|
N/A | |
Completed |
NCT00547040 -
Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
|
||
Completed |
NCT02821780 -
CADASIL Disease Discovery
|
||
Completed |
NCT05719090 -
Acute Effects of Autoregulated and Non-autoregulated Blood Flow Restrictive Exercise on Indices of Arterial Stiffness
|
N/A | |
Completed |
NCT04549324 -
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
|
||
Completed |
NCT05022498 -
Individual Variability of Coronary Heart Disease Risk Markers and Sleep Responses to Exercise
|
N/A | |
Completed |
NCT03415880 -
Light Intensity Physical Activity Trial
|
N/A | |
Completed |
NCT03560804 -
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs
|
N/A |